<DOC>
	<DOCNO>NCT00838201</DOCNO>
	<brief_summary>The purpose study describe safety tolerability 5 year ( ie , 3 year 20040138 Amgen study 2 year study ) denosumab administration measure adverse event , immunogenicity , safety laboratory parameter subject previously receive denosumab non-metastatic prostate cancer .</brief_summary>
	<brief_title>Extension Study Evaluate Long Term Safety Denosumab Subjects Undergoing ADT Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Subjects must currently participate 20040138 Amgen study Subjects must sign informed consent study specific procedure perform . Exclusion Criteria Subjects prior diagnosis bone metastasis Known hypocalcemia Developed sensitivity mammalian cell derive drug product 20040138 study Currently receive investigational product denosumab receive investigational product 20040138 study Any disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Androgen deprivation therapy non-metastatic prostate cancer</keyword>
</DOC>